Zeo ScientifiX (Zeo ScientifiX) Cash-to-Debt : 1.70 (As of Jan. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zeo ScientifiX's cash to debt ratio for the quarter that ended in Jan. 2024 was 1.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zeo ScientifiX could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Zeo ScientifiX's Cash-to-Debt or its related term are showing as below:

ZEOX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.2 Max: No Debt
Current: 1.7

During the past 13 years, Zeo ScientifiX's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.20.

ZEOX's Cash-to-Debt is ranked worse than
70.35% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs ZEOX: 1.70

Zeo ScientifiX Cash-to-Debt Historical Data

The historical data trend for Zeo ScientifiX's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zeo ScientifiX Cash-to-Debt Chart

Zeo ScientifiX Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash-to-Debt

Get a 7-Day Free Trial

0.20

1.29

0.13

3.62

2.53

Zeo ScientifiX Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															3.36	1.63	0.80	2.53	1.70

Competitive Comparison of Zeo ScientifiX's Cash-to-Debt

For the Biotechnology subindustry, Zeo ScientifiX's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zeo ScientifiX's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Cash-to-Debt falls into.

Zeo ScientifiX Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zeo ScientifiX's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.756	/	(0.68	+	0.013)
	=	2.53

Zeo ScientifiX's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1172	/	(673	+	17)
	=	1.70

Zeo ScientifiX (OTCPK:ZEOX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zeo ScientifiX Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3321 College Avenue, Suite 246, Davie, FL, USA, 33314

Website

https://www.organicell.com

Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.

Executives

Skycrest Holdings, Llc	10 percent owner	1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider	director, officer: CEO and Director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub	officer: Executive Vice President & CSO	23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich	officer: COO and Acting CEO	4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser	director	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn	director	2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz	director	58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi	director	6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh	director	E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste	director
Ryan C Likes	officer: Chief Operating Officer	1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell	10 percent owner, officer: Chief Financial Officer	77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani	director, officer: Chief Executive Officer	4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140